In vivo pharmacological evaluation of a lactose-conjugated luteinizing hormone releasing hormone analogue by Varasteh Moradi, Shayli et al.
Accepted Manuscript
Title: In vivo pharmacological evaluation of a
lactose-conjugated luteinizing hormone releasing hormone
analogue
Author: Shayli Varasteh Moradi Pegah Varamini Frederik
Steyn Istvan Toth
PII: S0378-5173(15)30190-3
DOI: http://dx.doi.org/doi:10.1016/j.ijpharm.2015.08.095
Reference: IJP 15178
To appear in: International Journal of Pharmaceutics
Received date: 22-5-2015
Revised date: 25-8-2015
Accepted date: 27-8-2015
Please cite this article as: Moradi, Shayli Varasteh, Varamini, Pegah, Steyn, Frederik,
Toth, Istvan, In vivo pharmacological evaluation of a lactose-conjugated luteinizing
hormone releasing hormone analogue.International Journal of Pharmaceutics
http://dx.doi.org/10.1016/j.ijpharm.2015.08.095
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
In vivo pharmacological evaluation of a lactose-conjugated luteinizing 
hormone releasing hormone analogue 
Shayli Varasteh Moradi 1, Pegah Varamini1, Frederik Steyn2 and Istvan Toth1,3 
 
1School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, 
Queensland 4072, Australia; 2 The University of Queensland Centre for Clinical Research and the 
School of Biomedical Sciences, The University of Queensland, St. Lucia, Queensland 4072, 
Australia; 3School of Pharmacy, The University of Queensland, Woolloongabba, Queensland 4102, 
Australia 
 
Graphical abstract 
 
Abstract: 
 
In the current study, the efficacy and pharmacokinetic profile of lactose-conjugated 
luteinizing hormone releasing hormone (LHRH) was examined following oral administration 
in male rats. A rapid and sensitive liquid chromatography/mass spectrometry technique was 
developed and applied for measuring the concentration of lactose[Q1][w6]LHRH (compound 
1) in rat plasma in order to allow measurement of pharmacokinetic parameters. LH release 
was evaluated using a sandwich ELISA. Maximum serum concentration (Cmax= 0.11 µg/ml) 
was reached at 2 h (Tmax) following oral administration of the compound at 10 mg/kg. The 
half-life was determined to be 2.6 h. The absolute bioavailability of the orally administered 
compound was found to be 14%, which was a remarkable improvement compared to zero-to-
low oral bioavailability of the native peptide. Compound 1 was effective in stimulating LH 
release at 20 mg/kg after oral administration. The method was validated at a linear range of 
0.01–20.0 µg/ml and a correlation coefficient of r2 ≥0.999. The accuracy and precision values 
showed the reliability and reproducibility of the method for evaluation of the 
pharmacokinetic parameters. These findings showed that the lactose derivative of LHRH has 
a therapeutic potential to be further developed as an orally active therapeutics for the 
treatment of hormone-dependent diseases. 
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1. Introduction 
 
LHRH is a neuroendocrine decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) 
secreted by hypothalamus in a pulsatile manner, which stimulates its cognate receptor in the 
pituitary gland to release gonadotropins including luteinising hormone (LH) and follicle-
stimulating hormone (FSH). Subsequently, the production of gonadotropins regulates the 
secretion of sex hormones in both males and females (Clayton and Catt, 1981). Due to the 
biological importance, various LHRH analogues have been designed and developed after 
LHRH was sequenced in 1971 (Matsuo et al., 1971; Schally et al., 1971). LHRH analogues 
are used clinically for the treatment of various hormone dependent diseases including prostate 
and breast cancers, endometriosis, fertility disorders and precocious puberty (Huirne and 
Lambalk, 2001). The continuous administration of LHRH or its agonists leads to an initial 
surge in the release LH, FSH and sex hormones subsequently, followed by down-regulation 
of the LHRH receptors and suppression of gonadotropin secretion (Millar et al., 2004).  
Endogenous LHRH has a short half-life of 4-8 min in human plasma (Barron et al., 
1982; Redding et al., 1973). It is also rapidly degraded by organs including liver, kidneys, 
anterior pituitary, posterior pituitary, and hypothalamus (Müller et al., 1997). Due to poor 
stability, LHRH is not able to provide a long-term stimulation of the pituitary gland and exert 
a strong and long-acting agonist effect. Replacement with D-amino acids at cleavage sites of 
native peptides improves their stability against enzymatic digestion and thereby prolongs the 
biological half-life. Substitution of Gly6 with D-amino acid in endogenous LHRH enhances 
the enzymatic resistance and also receptor binding affinity of the peptide, which leads to a 
better agonist activity (Coy et al., 1976; Schally AV, 2003). Triptorelin is a synthetic super 
agonist of LHRH containing D-Trp at position 6 with a longer half-life (19 min) than the 
native peptide (Barron et al., 1982) and is parenterally administered for prostate cancer 
treatment (Heyns, 2005). 
Although LHRH agonists have shown improved metabolic stability compared to the 
native peptide, they are still not orally effective. Poor membrane permeability and 
susceptibility to digestion by gastrointestinal enzymes give rise to a low oral bioavailability 
of LHRH agonists (less than 1%) (Iqbal et al., 2012). These analogues are distributed into the 
extracellular space and metabolized by digestive enzymes and kidney. It is believed that 
LHRH analogues are predominantly cleared by the kidney due to rapid and extensive renal 
uptake following IV administration (Handelsman and Swerdloff, 1986). All commercial 
analogues of LHRH are administered through parenteral routes including subcutaneous and 
intramuscular (Beyer et al., 2011; Padula, 2005). As the oral route is the preferred route of 
administration by patients, development of an oral delivery system for therapeutic peptides 
like LHRH is highly desirable. Manipulation of peptide structures using glycosylation 
strategy is known to be an effective approach to improve the metabolic stability and 
membrane permeability of modified analogues (Christie et al., 2014; Moradi et al., 2014; 
Powell et al., 1993). Glycosylation has been shown to improve the efficacy of some peptides 
in vitro and in vivo (Egleton et al., 2000; Wu et al., 2006; Yamamoto et al., 2009).  
Liquid chromatography/mass spectrometry (LC/MS) is a highly selective automated 
tool for quantitative sample analysis (Niessen, 2003). In addition to high sensitivity and 
selectivity, LC/MS has the advantage of providing data that are easy to interpret compared to 
other applicable techniques (Gillespie and Winger, 2011). Immunoassays are other routine 
techniques used for screening and quantification of peptides. However, these assays have 
some drawbacks such as higher incidence of false positive results and the requirement for 
specific antibodies. Therefore, developing an LC/MS-based method can provide highly 
accurate and reliable peptide quantification in biological samples (Sofianos et al., 2008).  
In our previous study, we showed that conjugation of glycosyl units to LHRH peptide 
enhanced the in vitro stability and permeability of the modified peptides across Caco-2 cell 
monolayers (as an intestinal model). Among all glycosylated analogues, lactose conjugated 
LHRH demonstrated the best in vitro stability and membrane permeability (Moradi et al., 
2013). In the current study, we measured the bioavailability and pharmacokinetic parameters 
of the lactose-modified LHRH as the lead compound in rats. An LC/MS-based method was 
developed for quantitative sample analysis followed by compound extraction from serum 
using an optimized method of extraction. The stimulatory effect of the orally administered 
compound on LH release in rats was also examined over 24 hours. 
 
2. Experimental 
2.1 Materials and apparatus  
Lactose[Q1][w6]LHRH (compound 1) and lactose[Q1]LHRH were synthesized according to 
the published methods (Moradi et al., 2013). Lactose[Q1]LHRH was used as the internal 
standard (IS). HPLC-grade acetonitrile (MeCN) was purchased from RCI Labscan Ltd. 
(Bangkok, Thailand). Methanol (MeOH) in HPLC grade was purchased from Merck 
biosciences (VIC, Australia) and Formic acid (analytical grade, 99%) from Univar, Australia. 
Phosphate buffer saline (PBS) was purchased from Invitrogen Life Technologies. 
 
2.2 Animals 
Male Sprague Dawley rats weighing between 140–170 g were purchased from UQ Animal 
Resource Centre (ARC) and were kept for one week acclimatization period prior to initiation 
of experimental procedures. Rats were housed in groups of two or three with ad libitum 
access to food and water, in a room with controlled temperature (22.2 ± 0.2 ◦C) and humidity 
(51–65%) on a photo period of 12 h light/12 h dark. For experiments, rats were divided into 3 
groups of 5 animals; negative control (PBS-treated group), intravenously (IV) and orally 
(PO) dosed groups. All experimental procedures were approved by The University of 
Queensland Animal Ethics Committee (AEC#SCMB/005/11/ARC). 
 
2.3 Sample preparation  
The rat plasma samples were thawed at room temperature and spiked with 100 µl of IS 
solution (to a final concentration of 1 µg/ml). Analytes were extracted from plasma using a 
liquid-liquid extraction method. Different concentrations of acidified MeCN (95%, 80% and 
60%) and MeOH (95%, 80% and 60%) with 0.1% formic acid were used to optimize the 
analyte extraction method. Plasma proteins were precipitated by the addition of 500 µl 
extraction solutions and were then vortexed and centrifuged at 14000 × g, 15 min. The 
supernatant was collected and evaporated under a slow stream of nitrogen gas using a five-
valve glass manifold. Extracted samples were reconstituted in 40 µl of water-acetonitrile-
formic acid (90:10:0.1) and injected into the LC/MS system for analysis.  
 
2.4 Preparation of calibration standards and quality control samples 
Stock solutions of compound 1 (100 µg/ml) and IS (10 µg/ml) were prepared in water: 
acetonitrile 90:10 containing 0.1% formic acid. Serial dilutions of the compound (60-0.2 
µg/ml) were then prepared from the stock solution to be used as calibration samples. 
Calibration standards were freshly prepared by spiking dilutions into blank rat plasma to 
yield final plasma concentrations ranging from 0.05 to 30.0 µg/ml of compound 1 and 1µg/ml 
of IS solution. Quality control (QC) samples at the lower limit of quantification (LLOQ), 
low, middle and high concentrations (0.01, 2, 10 and 20 µg/ml) were made daily from 
separately prepared stock solutions. The selected dilutions were added to 100 µL of plasma 
spiked with 20 µl of IS solution at a final concentration of 1 µg/ml). Similar extraction 
method was then used for the preparation of QC samples. Calibration curves were plotted as 
the peak area ratio (Compound 1:IS) vs concentration. 
 
2.5 LC–MS analysis and quantification 
LC/MS was carried out on a Shimadzu HPLC (LC-10AT) system coupled to a PE Sciex (AB 
Sciex) API 3000 triple quadrupole mass spectrometer (Applied Biosystems, Concord, 
Ontario, Canada). The instrument was operated in positive ion mode under the following 
conditions: Ion-Spray voltage, 5000 V; source temperature, 550 °C; curtain gas (nitrogen) at 
8; collision gas (nitrogen) at 5; declustring potential at 50; focusing potential at 220 and 
entrance potential at 10. Chromatographic separation was performed on a Phenomenex luna 
C18 column (5 μm, 50 mm × 2.0 mm) with a gradient mobile phase of solvent A (0.01% 
acetic acid in water) and solvent B (90% acetonitrile, 10% water and 0.01% acetic acid). The 
compound was eluted with a 20-35% solvent B over 5 min at a flow rate of 0.5 ml/min. Total 
injection volume was 15 µL. The extracted ion chromatogram with m/z 877.1 at 3.3–3.4 min 
and m/z 812.2 at 3.9–4.1 min was detected for compound 1 and IS, respectively. 
 
2.6 Method validation  
The accuracy and precision, calibration curve performance and recovery of the method were 
evaluated. The calibration curve was plotted in the range of 0.05-20 µg/ml using 1/x 
weighting regression model. Calibration curves were evaluated using three separately 
prepared batches. For testing the accuracy and precision of the method, intra- and inter-day 
assays were performed for all QC samples. The intra-day assay was performed within one 
day by analysing triplicate of each concentration of QC samples. The inter-day assay was 
carried out on four separate days for QC samples (each concentration in triplicate) and 
repeated twice (in two separate weeks). The recovery efficiency of the extraction procedure 
was performed at three concentrations of compound 1 (0.01, 10, and 20.0 µg/ml) and IS (1 
µg/ml) from rat plasma. 
 
2.7 In vivo pharmacokinetic study 
Rats were administered compound 1 at 2.5 mg/kg IV, 10 and 20 mg/kg PO. About 300 µL of 
blood sample was collected from each rat by tail bleed prior to the start of the experiment and 
at selected time points (0.5, 1, 2, 4, 6, 8, 12 and 24 h). Samples were allowed to clot for 2 h at 
room temperature, followed by centrifugation at 1000×g for 20 min. Serum aliquots were 
stored at −80◦C. 
  
 
2.8 LH release assay 
Serum concentration of LH was measured by a sandwich ELISA, strictly adhering to 
methodology as published previously (Steyn et al., 2013). Briefly, a 96-well high-affinity 
binding microplate was coated with monoclonal antibody (anti-bovine LH beta subunit) and 
incubated overnight at 4°C. A standard curve was generated using a 2-fold serial dilution of 
mouse LH in 0.2% (w/v) BSA-1×PBS-T (PBS with 0.05% Tween 20). The LH standards and 
plasma samples were incubated with 50 µL of detection antibody (polyclonal antibody, rabbit 
LH antiserum) for 1.5 h followed by the addition of 50 µL horseradish peroxidase-conjugated 
antibody (polyclonal goat anti-rabbit antibody) and 1.5 h incubation at room temperature. O-
phenylenediamine, substrate containing 0.1% H2O2 was added to each well and left at RT for 
30 minutes. The reaction was stopped using 3 M Hydrochloric acid. The absorbance of each 
well was read at a wavelength of 490 nm (Sunrise; Tecan Group). The concentration of LH in 
whole blood samples was determined by interpolating the OD values of unknowns against a 
nonlinear regression of the LH standard curve. LH secretory responses were expressed as the 
area under the curve (AUC) after normalizing data to the baseline value. The within and 
between assay coefficient of variation of LH assays were below 5%.  
 
2.9 Data analysis and statistical evaluation 
The pharmacokinetic profiles, including area under the plasma concentration vs. time curve 
(AUC), half-life (t1/2) and clearance (Cl) of each rat were analyzed by non-compartmental 
analysis (Phoenix WinNonlin 1.2; Certara Inc., Princeton, NJ, USA). The maximum plasma 
concentration (Cmax) and the time the Cmax is reached (Tmax) were directly computed from the 
plasma concentration vs. time graph. The oral bioavailability (F%) was calculated by the 
following equation: 
 
 
 
All the data are expressed as mean ± standard deviation. Statistical analysis of 
pharmacokinetic parameters was calculated using ANOVA followed by the Dunnett’s post 
hoc test. 
 
 
 
 
 
3. Results  
3.1 Method validation and quantification of compound 1 in rat plasma 
The chemical structures of compound 1 and compound 2 (IS) are shown in Fig. 1. 
Lactose[Q1]LHRH was used as IS due to the structural similarity to compound 1. The 
extraction of compound from rat plasma was performed using different concentrations of 
acidified MeOH and MeCN solutions. Among all extraction solutions tested, the best 
recovery of compound 1 and IS from rat plasma was obtained using 95% of MeCN in water. 
The recovery (%) was found to be above 80% for 0.05, 2 and 10 µg/ml of compound 1 
(83.7%, 89.8%, and 91.3%, respectively).  
The calibration curve showed an acceptable linearity at r2=0.999 for the range of 
concentration used, from 0.05 to 20 µg/ml (Fig. S1). The lower limit of quantification 
(LLOQ) was 0.01 µg/ml. The reproducibility of the method was confirmed by intra- and 
inter-day assays which were determined by analysing the LLOQ (0.01 µg/ml), low QC (2 
µg/ml, n=3), medium QC (10 µg/ml, n=3) and high QC (20 µg/ml, n=3) on four separate 
runs. The inter-day precision did not exceed 12% for the four concentrations of QC samples 
and the intra-day precision of the assay was between 2% and 15%. The accuracy of intra- and 
inter-day assays ranged from 95% to 105% for the analyte and IS (Table S. I). 
The method selectivity was determined by analysing the plasma samples spiked with 
the highest concentration of compound 1 without IS. No signal was detected for IS showing 
that there was no interference of the IS signal with the compound’s peak. Analysis of four 
sources of blank plasma prepared from different rats showed no signal for compound 1 and 
IS indicating that source of plasma did not affect the signals obtained from compound 1 and 
IS. 
 
 
 
 
3.2 Pharmacokinetic studies  
Pharmacokinetic parameters were analysed by non-compartmental analysis. The results are 
summarised in Table I as mean±SD of measurements from five animals per group. Following 
IV and PO administrations, the plasma concentration of the compound at various time points 
(during 24 h) was measured using the established LC/MS method (Fig. 2). The AUCs were 
obtained at 1.27±0.76 µg/ml*h and 0.709±0.24 µg/ml*h for IV and PO doses, respectively. 
The mean volume of distribution (Vd) and clearance of compound 1 were found to be 36.49 
ml/kg and 1.96±0.52 ml/h/kg, respectively, after IV administration. The peak plasma 
concentration of the compound was achieved after 2 h (Cmax= 0.11±0.03 µg/ml). The half-life 
of compound 1 in plasma was 2.6 h after PO dose, which was a significant improvement 
compared to the short half-life of native LHRH as reported in literature (4 min) (Redding et 
al., 1973). The oral bioavailability of the compound was measured to be 14%. 
 
 
Table 1: Pharmacokinetic parameters of compound 1 in rats after administration at 2.5 mg/kg 
IV and 10 mg/kg PO. Data are presented as mean ± SD (n = 5). 
Parameters        Value (Mean+SD)      Value (Mean+SD) 
                                          IV                               PO 
Body weight (g)            171±25.08             164.4±18.40 
AUC0-∞ (µg/ml*h)       1.27±0.76               0.709±0.24 
T1/2 (h)                            2.9±0.63                2.6±0.84 
Cl (ml/h/kg)                 1.96±0.52                      - 
Vd (ml/kg)                     36.49                            - 
Cmax (µg/ml)                     -                            0.11±0.03 
Tmax  (h)                             -                            2 
F (%)                                 -                           14 
 
 T1/2: half-life; Cl: clearance; Vd: volume of distribution; Cmax: maximum concentration; Tmax: 
time to reach Cmax. 
 
3.3 Efficacy of compound 1 in the release of LH  
To determine the changes in LH level after oral administration of compound 1, the 
normalised area under curves (nAUC) of LH released was obtained over 24 h. A marked 
increase in the level of LH was observed after oral administration of 20 mg/kg of compound 
1 compared to the control (PBS) group (from nAUC=4.45± 1.028 ng/24h in control group to 
nAUC=11.33± 1.65 ng/24h). However, the oral dose of 10 mg/kg did not stimulate the 
release of LH significantly over 24 h (Fig. 3). 
 
4. Discussion 
In the present study, the pharmacological properties of lactose-[Q1][w6]LHRH was evaluated 
after PO and IV administration to rats. Due to the poor oral bioavailability, all commercial 
derivatives of LHRH are administered parenterally which is inconvenient for patients. The 
main objective of this research was to improve the bioavailability of LHRH following oral 
administration. Modification of therapeutic peptides by substitution of D-isoform of amino 
acids is known to be the effective strategy to improve their pharmacological properties and 
metabolic stability (Seitz, 2000; Werle and Bernkop-Schnürch, 2006). Glycosylation is 
another useful approach to improve the metabolic stability of peptides in physiological 
environments and increase their biological activity (Simerska et al., 2009; Ueda et al., 2009). 
We applied D-amino acid substitution together with glycosylation strategy to address the 
associated challenges and enhance the bioavailability of LHRH peptide. In our preliminary in 
vitro studies, we showed that glycosylation significantly enhanced the metabolic stability (up 
to 4-fold) and apparent permeability (7 to 15-fold) of LHRH across intestinal cell membranes 
(Moradi et al., 2013; Moradi et al., 2014). Based on those results, we selected compound 1 as 
the most promising LHRH glycosylated derivative for oral administration and investigated 
the pharmacological profile of this analogue followed by oral administration to rats.  
For pharmacokinetic evaluation of compound 1, an accurate analytical tool was required to 
determine the peptide’s plasma concentration. Therefore, an LC/MS method was developed 
and validated for quantitation purposes. LC/MS is an automated technique with broad 
applications in quantification of pharmaceutical compounds and their metabolites in 
biological matrices. The selectivity, sensitivity and cost effectiveness of MS based methods 
make them a preferred analytical technique in pharmaceutical industry (Lee, 2003). The 
developed method in this study was capable of detecting the compound over a range of 0.01 
to 20 µg/ml with a detection limit of 0.01 µg/ml. The precision and accuracy of the method 
was assessed by performing intra- and inter-day assays The precision value obtained was 
below 12% for the four QC levels which was in acceptable limit based on FDA guidelines 
(the precision value should not exceed 15%) (Rower et al., 2010). The high accuracy (98.2% 
and 97.9% for intra-day and inter-day, respectively) was also obtained showing the reliability 
of the developed method. Consequently, the validation of the method showed good 
reproducibility, accuracy, precision and linearity for quantification of compound 1 in rat 
plasma.  
A quick and easy extraction protocol was performed for precipitation of plasma 
proteins using liquid-liquid extraction method. It yielded over 80% recovery for three 
selected concentration of the compound. The high and consistent extraction recovery showed 
a negligible loss of the analyte during the sample preparation process, and did not vary from 
sample to sample. 
A significant improvement in the bioavailability (14%) and half-life of compound 1 
(2.6 h) was observed after oral administration of compound 1 compared to the endogenous 
peptide (Iqbal et al., 2012; Redding et al., 1973). The increased half-life of the compound 
may account for the enhancement of its bioavailability. These findings demonstrate that the 
attachment of lactose to LHRH analogue significantly improved the pharmacological 
properties of native LHRH. This is in agreement with other studies we previously published 
showing that the modification of opioid peptide endomorphin-1 by a lactose moiety resulted 
in significant analgesic activity of the peptide following oral administration to rats (Varamini 
et al., 2012). To the best of our knowledge, this is the first report of an orally administered 
LHRH analogue with a remarkable half-life and bioavailability.  
Acute administration of LHRH agonists stimulates the pituitary gland to release LH, 
whereas the chronic administration results in suppression of the pituitary-gonadal axis and 
blockade of LH secretion (Pinski et al., 1996). Following single-dose oral administration 
(acute administration) of compound 1 to rats, their plasma LH level increased significantly 
compared to the negative control group. This finding demonstrated that compound 1 was able 
to produce stimulatory effect in vivo following acute administration. Taken together, we 
improved the oral bioavailability of LHRH by conjugation of a lactose moiety and D-Tyr6 
substitution while maintaining the activity.  
 
5. Conclusions 
In the present study, we applied glycosylation strategy together with D-amino acid 
substitution to develop an orally active LHRH analogue. A sensitive and specific LC/MS 
quantification method was developed and validated to evaluate the pharmacological activity 
of lactose-[Q1][w6]LHRH in vivo. The method was reproducible and reliable to be used for 
quantitative analysis of the compound in rat plasma. We showed that the conjugation of 
lactose residue to LHRH peptide increased its half-life and oral bioavailability in rats 
significantly. The newly designed analogue could also stimulate LH secretion upon oral 
administration. The improved pharmacological properties of lactose-[Q1][w6]LHRH render 
this analogue a promising candidate towards the development of an orally available LHRH 
therapeutics. 
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Figure captions 
Figure 1: Chemical structures of (A) lactose [Q1][w6]LHRH (compound 1)  and (B) lactose 
[Q1]LHRH (Compound 2; IS). 
Figure 2: Plasma levels of compound 1 (mean ± SD, n=5) following 2.5 mg/kg IV bolus (A) 
and 10 mg/kg oral gavage (B) in intact male rats measured by LC/MS. 
 
Figure 3:  Changes in the plasma level of LH calculated from a nAUC over 24 h following 
oral administration of compound 1 at 10 and 20 mg/kg. Each column represents the Mean ± 
SD (n=5). Statistical analysis was performed using a one-way ANOVA followed by the 
Dunnett’s post hoc test and compared to PBS group (***, p<0.01). 
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